Rein Therapeutics Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: —
EBITDA: +60.1%
EBIT: -23.3%
EPS: +33.3%
Free cash flow: +28.4%
Operating cash flow: +28.4%

Forward estimates

Revenue: —
EBITDA: —
EPS: —

Three-year CAGR

Revenue: —
EBITDA: -80.3%
EBIT: +66.3%
Net income: +20.7%
EPS: +44.2%
Free cash flow: +13.1%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.